Clinical Trial Update: Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose [Phase 1]

View source ↗

Summary

A Phase 1 trial by Eli Lilly assessing how LY2189265 affects insulin secretion in response to intravenous glucose in individuals with Type 2 diabetes; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LY2189265

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2014-10-07